TECHNETIUM TC-99M SESTAMIBI KIT - Generic Drug Details

What are the generic sources for technetium tc-99m sestamibi kit and what is the scope of patent protection?

Technetium tc-99m sestamibi kit is the generic ingredient in three branded drugs marketed by Lantheus Medcl, Cardinal Health 414, Curium, Jubilant Draximage, and Sun Pharm Inds Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound.

Summary for TECHNETIUM TC-99M SESTAMIBI KIT

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	4
Clinical Trials:	7
DailyMed Link:	TECHNETIUM TC-99M SESTAMIBI KIT at DailyMed

Recent Clinical Trials for TECHNETIUM TC-99M SESTAMIBI KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GE Healthcare	Early Phase 1
M.D. Anderson Cancer Center	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all TECHNETIUM TC-99M SESTAMIBI KIT clinical trials

Pharmacology for TECHNETIUM TC-99M SESTAMIBI KIT

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for TECHNETIUM TC-99M SESTAMIBI KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	AP	RX	Yes	Yes
Curium	TECHNETIUM TC 99M SESTAMIBI	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	078098-001	Sep 22, 2008	AP	RX	No	No
Sun Pharm Inds Inc	TECHNETIUM TC 99M SESTAMIBI	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	079157-001	Jul 10, 2009		DISCN	No	No

Expired US Patents for TECHNETIUM TC-99M SESTAMIBI KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990
Lantheus Medcl	MIRALUMA	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-003	May 23, 1997
Lantheus Medcl	MIRALUMA	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-003	May 23, 1997

TECHNETIUM TC-99M SESTAMIBI KIT Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Drivers for Technetium Tc-99m Sestamibi Kits?

Technetium Tc-99m sestamibi kits are critical for diagnostic imaging, primarily used in myocardial perfusion imaging (MPI) and breast cancer detection. The market is driven by several factors:

• Growing prevalence of cardiovascular diseases (CVD) and breast cancer.
• Increased demand for non-invasive diagnostic procedures.
• Expansion of nuclear medicine facilities worldwide.
• Technological improvements enhancing imaging quality.
• Regulatory approvals and reimbursement policies encouraging adoption.

Global CVD prevalence reached 526 million cases in 2020, with an annual growth rate of 3.2%. Breast cancer accounted for 2.3 million new cases in 2020. The rise of these conditions sustains demand for SPECT/TPET scans using technetium-99m (Tc-99m).

How Does the Supply Chain Influence Market Dynamics?

The supply chain is concentrated around nuclear reactors producing molybdenum-99 (Mo-99), which decays to Tc-99m—the isotope within these kits.

• The U.S. relies heavily on imports, particularly from Canada and South Africa.
• Production disruptions, like shutdowns of reactors in 2018-2019, caused shortages.
• The aging reactor infrastructure (predominantly aged aging reactors in Canada) remains a risk.
• Countries are investing in domestic Mo-99/ Tc-99m production to reduce dependency.

In 2019, the global Mo-99 supply faced its first significant shortage since 2009, impacting distributions of Tc-99m kits.

What Is the Current Market Size and Financial Trajectory?

The global nuclear medicine market, inclusive of diagnostic and therapeutic radiopharmaceuticals, was valued at USD 4.7 billion in 2021. Tc-99m-based diagnostics account for over 80% of the market.

• The Tc-99m generator segment alone generated approximately USD 3.0 billion in 2021.
• The compound annual growth rate (CAGR) for the market is projected at 4.5% from 2022 to 2030.
• The Asia-Pacific region is experiencing the fastest growth, with CAGR reaching 6% due to expanding healthcare infrastructure and rising disease burden.

Leading manufacturers include Nordion (Thermo Fisher), Curium (NorthStar), and Lantheus Medical Imaging. They account for over 70% of global market share.

What Are Market Challenges and Risks?

• Dependence on Mo-99 supplies from aging reactors.
• Regulatory hurdles for new radiopharmaceutical approvals.
• Short half-life of Tc-99m (6 hours) complicates logistics.
• Limited shelf life demands fast distribution logistics, which can be disrupted.
• Competition from alternative diagnostic modalities like PET, MRI, and CT scans.

What Are the Innovation Trends?

• Development of alternative radiotracers with longer shelf lives.
• Investment in cyclotron-based production of Tc-99m.
• Automation of kit preparation to improve safety and consistency.
• Digital integration in imaging devices to enhance diagnostic accuracy.

How Do Regulatory Policies Affect Market Growth?

Regulatory bodies in North America and Europe have implemented policies favoring the use of nuclear medicine diagnostics, including:

• Reimbursement codes that incentivize scan procedures.
• Approval pathways supporting simplified registration for new kits.
• Initiatives promoting domestic Mo-99 production, such as the U.S. Advanced Medical Isotope Program.

What Are Future Market Outlooks?

The demand for Tc-99m kits is expected to grow moderately, with an annual increase of around 4.5%. The expansion of healthcare infrastructure in emerging markets, alongside technological innovations and supply stability initiatives, supports continued growth.

The focus on alternative production methods, like cyclotrons, aims to reduce reliance on aging reactors. Addressing logistical challenges and regulatory hurdles will remain vital.

Key Takeaways

• The global Tc-99m kit market is driven by rising CVD and breast cancer cases and technological advances.
• Supply chain vulnerabilities due to aging reactors impact market stability.
• The market size was USD 3 billion in 2021; projected CAGR is 4.5% through 2030.
• Asia-Pacific presents the fastest growth opportunities.
• Innovations aim to mitigate supply risks and extend shelf life, supporting long-term demand.

FAQs

1. What is the primary use of technetium Tc-99m sestamibi kits?
They are used predominantly for myocardial perfusion scans and breast cancer detection.

2. How does supply chain disruption affect the market?
Reactor shutdowns cause shortages, limiting kit availability and slowing market growth.

3. What innovations are shaping the market?
Cyclotron-based Tc-99m production, automation, and development of alternative tracers.

4. Which regions are experiencing the fastest market growth?
The Asia-Pacific region due to expanding healthcare infrastructure and disease burden.

5. What regulatory trends support market expansion?
Enhanced approval pathways and government initiatives to establish domestic Mo-99 production.

References

1. World Health Organization. Cardiovascular diseases factsheet, 2020.
2. GLOBOCAN. Breast cancer statistics, 2020.
3. MarketsandMarkets. Nuclear medicine market analysis, 2022.
4. U.S. National Academies of Sciences, Engineering, and Medicine. Improving isotope supply, 2018.
5. IAEA. Nuclear medicine diagnostics and radiopharmaceuticals, 2021.